New Orleans, LA (PRWEB) April 13, 2013
Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced the launch of the company’s next-generation Surefire Infusion System and Specialty Catheters at the Society of Interventional Radiology (SIR) 38th Annual Meeting, held in New Orleans April 13-18. The new ST and LT microcatheters can accommodate smaller vessels and selective procedures in direct-to-tumor cancer treatment.
Now available in the U.S., Europe, Canada and New Zealand, the company’s new Surefire Infusion System--ST and Surefire Infusion System--LT microcatheters for the interventional radiology and interventional oncology markets are distinguished by their expandable tip. When deployed, the tip expands dynamically to the walls of the artery, preventing any damage caused by backflow into healthy, non-target vessels and tissues.
“The new Surefire Infusion System makes some treatment dilemmas far less problematic, and thus may improve patient safety. However, the far more exciting aspect of the new system is the potential for improving the efficacy of therapy, said Fred Moeslein, M.D., Interim Director, Division of Vascular and Interventional Radiology, University of Maryland School of Medicine.
“Currently, Drug-Eluting Bead Chemoembolization (DEB-TACE) is performed routinely across this country and around the globe using end-hole catheters. Often, especially in the setting of hypovascular tumors or heavily pretreated tumors, stasis is reached early, thus limiting drug delivery. The Surefire system allows us to deliver more drug to the tumor, even in the setting of stasis without risk of reflux or non-target embolization. Therefore the new system gives us the capability to control drug delivery far better than with a standard end-hole catheter.”
In addition, newly published data in the Journal of Vascular and Interventional Radiology show Surefire’s technology significantly increases penetration of embolic agents at the targeted cancer site, to 99.9 percent compared to 72.8 percent when using end-hole catheters.
The Surefire Infusion System--ST for vessels from 3mm to 4.5 mm in size, and the Surefire Infusion--LT for larger vessels from 4 mm to 6 mm in size, are used in diagnostic and therapeutic procedures to deliver radiopaque media and embolization agents to selected sites in the peripheral vascular system.
Surefire’s New Specialty Catheters
Also introduced today are Surefire’s Specialty Catheters, the Simmons 1 and Axis, available in a variety of different curve styles for accessing the wide range of patient anatomies.
“Surefire’s ST and LT microcatheters and Specialty Catheters are rapidly proving to better meet clinical needs in targeted delivery of embolics,” said Surefire CEO and President Jim Chomas.
The Surefire Infusion System-ST, LT and Specialty Catheters have received regulatory approval in the U.S., Europe, and New Zealand.
SIR Booth Speaker Schedule
The following experts will discuss new techniques made possible by the Surefire Infusion System ST-LT at Surefire Medical booth #1847:
About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. For more information, please visit http://www.surefiremedical.com.
# # # #
Read the full story at http://www.prweb.com/releases/2013/4/prweb10628816.htm.
Copyright©2012 Vocus, Inc.
All rights reserved